BNP Paribas Financial Markets Acquires New Shares in BioNTech SE (NASDAQ:BNTX)

BNP Paribas Financial Markets bought a new position in shares of BioNTech SE (NASDAQ:BNTX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 614,297 shares of the company’s stock, valued at approximately $69,999,000.

Other institutional investors also recently bought and sold shares of the company. Jones Financial Companies Lllp raised its stake in shares of BioNTech by 110.3% during the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after buying an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. raised its position in BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after acquiring an additional 700 shares during the last quarter. Allianz SE purchased a new stake in shares of BioNTech in the fourth quarter valued at about $90,000. GAMMA Investing LLC grew its position in shares of BioNTech by 48.2% in the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after purchasing an additional 300 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. purchased a new position in shares of BioNTech during the 4th quarter worth approximately $137,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Stock Performance

NASDAQ:BNTX opened at $94.74 on Wednesday. The firm’s fifty day simple moving average is $99.87 and its 200 day simple moving average is $109.87. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49. The firm has a market capitalization of $22.73 billion, a price-to-earnings ratio of -45.11 and a beta of 1.35.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.24 billion. During the same quarter in the previous year, the firm posted $1.90 earnings per share. The firm’s quarterly revenue was down 19.5% on a year-over-year basis. As a group, equities research analysts expect that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on BNTX. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.44 target price on shares of BioNTech in a research note on Tuesday, March 11th. BMO Capital Markets upped their price objective on BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. Citigroup reaffirmed a “buy” rating and set a $140.00 price objective (down previously from $145.00) on shares of BioNTech in a research note on Tuesday. HC Wainwright reduced their target price on shares of BioNTech from $150.00 to $145.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Finally, Truist Financial assumed coverage on shares of BioNTech in a report on Friday, January 10th. They set a “buy” rating and a $172.00 price target for the company. Three investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus target price of $142.73.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.